Etrolizumab

Etrolizumab is a humanized IgG1 monoclonal antibody that targets the β7 subunit of the integrins α4β7 and αEβ7. It was developed as a gut-selective therapy for inflammatory bowel diseases, specifically ulcerative colitis and Crohn's disease. Etrolizumab exerts its effects through a dual mechanism of action by inhibiting both leukocyte trafficking to the intestinal mucosa (via blockade of α4β7–MAdCAM-1 interactions) and retention of leukocytes within the intraepithelial lining of the gut (via blockade of αEβ7–E-cadherin interactions). This dual inhibition reduces inflammation in the gastrointestinal tract while sparing other tissues, contributing to its favorable safety profile compared to other anti-integrin therapies[1][3][5][6]. The drug does not bind to α4β1 integrin, which is important for lymphocyte migration outside the gut[3][5]. Etrolizumab was primarily developed by Genentech/Roche for moderate-to-severe ulcerative colitis and Crohn's disease but has not achieved regulatory approval as clinical trials did not meet primary endpoints in phase III studies[2][7].

Other names

monoclonal antibody beta7recombinant-human-monoclonal-antibody-beta7recombinant-human-monoclonal-antibody-beta-7recombinant-human-monoclonal-antibody-beta 7